Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Expert Review of Anticancer Therapy

• Publication date

  2009-11-01

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1586/era.09.129PMID 19895245
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Radiation therapy-related toxicity (including pneumonitis and fibrosis).

  2010cited by this paper
• Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.

  2009cited by this paper
• Limb sparing treatment of bleeding melanoma recurrence by electrochemotherapy.

  2009cited by this paper
• Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology

  2009cited by this paper
• Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

  2009cited by this paper
• Novel therapeutics for the treatment of metastatic melanoma.

  2009cited by this paper
• Radiation therapy-related toxicity (including pneumonitis and fibrosis).

  2009cited by this paper
• Surgery and adjuvant therapies in the treatment of stage IV melanoma: our experience in 84 patients

  2009cited by this paper
• Electrochemotherapy of tumours

  2009cited by this paper
• Surgery and radiotherapy in the treatment of cutaneous melanoma

  2009cited by this paper
• Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases

  2009cited by this paper
• Melanoma epidemiology and public health.

  2009cited by this paper
• Autologous Melanoma Vaccine Induces Antitumor and Self-Reactive Immune Responses That Affect Patient Survival and Depend on MHC Class II Expression on Vaccine Cells

  2009cited by this paper
• Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

  2009cited by this paper
• A randomized phase III trial of biochemotherapy versus interferon-&agr;-2b for adjuvant therapy in patients at high risk for melanoma recurrence

  2009cited by this paper
• Immunotherapy of distant metastatic disease

  2009cited by this paper
• Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

  2009cited by this paper
• Utility of adjuvant systemic therapy in melanoma

  2009cited by this paper
• Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion

  2008cited by this paper
• Biochemotherapy for the treatment of metastatic malignant melanoma: a clinical practice guideline

  2008cited by this paper
• Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

  2008cited by this paper
• Radiation therapy toxicity to the skin.

  2008cited by this paper
• Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma

  2008cited by this paper
• Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.

  2008cited by this paper
• Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?

  2008cited by this paper
• Electrochemotherapy with Intravenous Bleomycin in the Local Treatment of Skin Melanoma Metastases

  2008cited by this paper
• Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

  2008cited by this paper
• Bleomycin-Based Electrochemotherapy: Clinical Outcome from a Single Institution’s Experience with 52 Patients

  2008cited by this paper
• Immune gene therapy as a neoadjuvant to surgical excision to control metastatic cancers.

  2008cited by this paper
• p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.

  2008cited by this paper
• Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou

  2008cited by this paper
• Chimeric Receptor mRNA Transfection as a Tool to Generate Antineoplastic Lymphocytes

  2008cited by this paper
• Electroporation for drug and gene delivery in the clinic: doctors go electric.

  2008cited by this paper
• Adoptive Cell Therapy for Patients with Melanoma, Using Tumor-Infiltrating Lymphocytes Genetically Engineered to Secrete Interleukin-2

  2008cited by this paper
• Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.

  2008cited by this paper
• Therapy for unresectable recurrent and in-transit extremity melanoma.

  2008cited by this paper
• Trastuzumab in the adjuvant setting: concurrent or sequential? It takes two to tango!

  2008cited by this paper
• Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

  2008cited by this paper
• The European approach to in-transit melanoma lesions

  2008cited by this paper
• Electrochemotherapy in treatment of tumours.

  2008cited by this paper
• Electrochemotherapy: An emerging cancer treatment

  2008cited by this paper
• EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

  2008cited by this paper
• Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope.

  2008cited by this paper
• Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses

  2008cited by this paper
• Electrochemotherapy of Mycosis fungoides by interferon-α

  2007cited by this paper
• DC-based cancer vaccines.

  2007cited by this paper
• A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma

  2007cited by this paper
• Effective treatment of multiple unresectable skin melanoma metastases by electrochemotherapy.

  2007cited by this paper
• Electrochemotherapy of Mycosis fungoides by interferon-alpha.

  2007cited by this paper
• Vaccine therapy for melanoma: current status and future directions.

  2007cited by this paper
• Temozolomide for the treatment of metastatic melanoma: a systematic review.

  2007cited by this paper
• Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.

  2007cited by this paper
• Electrochemotherapy: Aspects of Preclinical Development and Early Clinical Experience

  2007cited by this paper
• Randomized adjuvant therapy trials in melanoma: surgical and systemic.

  2007cited by this paper
• In Vivo Electroporation for Gene Therapy

  2006cited by this paper
• Randomized Controlled Study of Electrochemotherapy in the Local Treatment of Skin Metastases of Melanoma

  2006cited by this paper
• Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study

  2006cited by this paper
• In vivo results of a new focal tissue ablation technique: irreversible electroporation

  2006cited by this paper
• Nanosecond pulsed electric fields cause melanomas to self-destruct

  2006cited by this paper
• Solitary and Multiple Isolated Metastases of Clear Cell Renal Carcinoma to the Pancreas: An Indication for Pancreatic Surgery

  2006cited by this paper
• Bases and rationale of the electrochemotherapy

  2006cited by this paper
• Long lasting complete response in melanoma treated by electrochemotherapy

  2006cited by this paper
• Non-viral in vivo immune gene therapy of cancer: combined strategies for treatment of systemic disease

  2006cited by this paper
• Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.

  2006cited by this paper
• Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000.

  2006cited by this paper
• Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues.

  2006cited by this paper
• The state-of-the-art of electrochemotherapy before the ESOPE study; advantages and clinical uses

  2006influential reference
• Electrically-assisted nucleic acids delivery to tissues in vivo: where do we stand?

  2006cited by this paper
• Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes

  2006cited by this paper
• Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours.

  2006cited by this paper
• Local gene therapy of solid tumors with GM-CSF and B7-1 eradicates both treated and distal tumors

  2006cited by this paper
• Cryosurgery for advanced malignant melanoma of the facial skin. A case report.

  2006cited by this paper
• Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors

  2006cited by this paper
• Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

  2006cited by this paper
• Plasma membrane voltage changes during nanosecond pulsed electric field exposure.

  2006cited by this paper
• Cutaneous Melanoma Subtypes Show Different BRAF and NRAS Mutation Frequencies

  2006cited by this paper
• Radiosensitising effect of electrochemotherapy with bleomycin in LPB sarcoma cells and tumors in mice

  2005cited by this paper
• Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy)

  2005cited by this paper
• TNFerade, an Adenovector Carrying the Transgene for Human Tumor Necrosis Factor α, for Patients With Advanced Solid Tumors: Surgical Experience and Long-Term Follow-Up

  2005cited by this paper
• Interleukin-2 for the treatment of melanoma.

  2005cited by this paper
• BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs

  2005cited by this paper
• Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

  2005cited by this paper
• A case of perineal malignant melanoma successfully treated with electrochemotherapy.

  2005cited by this paper
• Successful sphincter-saving treatment of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy.

  2005cited by this paper
• [Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma].

  2004cited by this paper
• TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.

  2004cited by this paper
• Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas

  2004cited by this paper
• Mature results of a phase III randomized trial of bacillus Calmette–Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I–III melanoma (E1673)

  2004cited by this paper
• Komplette Remission kutaner Satelliten- und In-transit-Filiae nach intraläsionaler Interleukin-2-Applikation bei 2 Patienten mit malignem Melanom

  2004cited by this paper
• The Development of Novel Flexible Electrode Arrays for the Electrochemotherapy of Solid Tumour Tissue. (Potential for Endoscopic Treatment of Inaccessible Cancers)

  2004cited by this paper
• Management of in‐transit metastases from cutaneous malignant melanoma

  2004cited by this paper
• The role of isolated limb perfusion for melanoma confined to the extremities.

  2003cited by this paper
• Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research.

  2003cited by this paper
• Determinants of BRAF mutations in primary melanomas.

  2003cited by this paper
• Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.

  2003cited by this paper
• Interleukin-2–Independent Proliferation of Human Melanoma-Reactive T Lymphocytes Transduced With an Exogenous IL-2 Gene Is Stimulation Dependent

  2003cited by this paper
• Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.

  2003cited by this paper
• Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

  2003cited by this paper
• Electrochemotherapy: advantages and drawbacks in treatment of cancer patients

  2003cited by this paper
• Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas

  2003cited by this paper

• Potential dual synergy between electrochemotherapy and sequence of immunotherapies in metastatic melanoma: A case report.

  2023cites this paper
• CANINE SQUAMOUS CELL CARCINOMA: ELECTROCHEMOTHERAPY ASSOCIATION WITH SURGERY AND CORRELATION WITH OVERALL SURVIVAL.

  2023cites this paper
• Phosphatidylserine: The Unique Dual-Role Biomarker for Cancer Imaging and Therapy

  2022cites this paper
• Electroporation in Head-and-Neck Cancer: An Innovative Approach with Immunotherapy and Nanotechnology Combination

  2022cites this paper
• Electrochemotherapy and Other Clinical Applications of Electroporation for the Targeted Therapy of Metastatic Melanoma

  2021cites this paper
• Large Liver Blood Vessels and Bile Ducts Are Not Damaged by Electrochemotherapy with Bleomycin in Pigs

  2019cites this paper
• Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options

  2019cites this paper
• Electrochemotherapy - Emerging applications technical advances, new indications, combined approaches, and multi-institutional collaboration.

  2019cites this paper
• Electrochemotherapy in the treatment of melanoma

  2018cites this paper
• Treatment of Metastatic Melanoma

  2018cites this paper
• Electrochemotherapy in Breast Cancer - Discussion of the Method and Literature Review

  2017cites this paper
• Electrochemotherapy: An enhancement of cytotoxicity of anticancer drugs

  2017cites this paper
• CD4+FOXP3+ T regulatory cells decrease and CD3+CD8+ T cells recruitment in TILs from melanoma metastases after electrochemotherapy

  2016cites this paper
• Intralesional immunotherapy as a strategy to treat melanoma

  2016cites this paper
• Influence of Electrodes on Electric Field Distribution for Effective Electrochemotherapy

  2016cites this paper
• Influence of Electrodes on Electric Field Distribution for Effective Electrochemotherapy

  2016cites this paper
• Electroporation in veterinary oncology.

  2016cites this paper
• Electrochemotherapy in melanoma patients: a single institution experience.

  2015cites this paper
• omplete regression of melanoma skin etastases after electrochemotherapy plus pilimumab treatment : an unusual clinical

  2015cites this paper
• Complete regression of melanoma skin metastases after electrochemotherapy plus ipilimumab treatment: an unusual clinical presentation

  2015cites this paper
• Matlab-based tool for ECG and HRV analysis

  2014cites this paper
• Note atlab-based tool for ECG and HRV analysis

  2014cites this paper
• Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy

  2014cites this paper
• Electrochemotherapy in Breast Cancer: A Review of References.

  2014cites this paper
• Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations

  2014cites this paper
• Treatment of metastatic melanoma with electrochemotherapy

  2014cites this paper
• Desmoplastic melanoma on the nose: electrochemotherapy as an alternative treatment to local advanced disease

  2014cites this paper
• Electrochemotherapy in Breast Cancer: A Review of References Elektrochemotherapie beim Mammakarzinom: eine Literaturübersicht

  2014cites this paper
• Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis

  2013cites this paper
• Malignant wound management in advanced illness: new insights

  2013cites this paper
• Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis.

  2013cites this paper
• Electroporation Based Drug Delivery and Its Applications

  2013cites this paper
• In situ Ablation of Solid Tumors by Electric Forces and Its Effect on the Tumor Microenvironment and Anti-tumor Immunity

  2013cites this paper
• Tumor size and effectiveness of electrochemotherapy

  2013influential citation
• Chapter 3 Electroporation Based Drug Delivery and Its Applications

  2013cites this paper
• Drug delivery by electropulsation: Recent developments in oncology.

  2012cites this paper
• Electrochemotherapy of chest wall breast cancer recurrence.

  2012cites this paper
• Utility of electrochemotherapy in melanoma treatment

  2012cites this paper
• Electrical field analysis of pentagonal needle array electrode for electrochemotherapy applications

  2012cites this paper
• Surgical treatment of melanoma: from excision to sentinel node biopsy

  2012cites this paper
• The dielectric properties of electroporated human breast cancer cells

  2012cites this paper
• Microsecond and nanosecond electric pulses in cancer treatments

  2012cites this paper
• Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy

  2012cites this paper
• Electric field distribution of malignant breast tissue under needle electrode configuration

  2012cites this paper
• Muscle gene electrotransfer is increased by the antioxidant tempol in mice

  2011cites this paper
• The Role of Electrochemotherapy in the Treatment of Malignant Melanoma

  2011cites this paper
• Treatment of Melanoma by Electroporation of Bacillus Calmette-Guerin

  2011cites this paper
• Identification of In Vitro Electropermeabilization Equivalent Pulse Protocols

  2011cites this paper
• Cutaneous Metastases from Malignant Melanoma: Clinical Features and New Therapeutic Perspectives

  2011cites this paper
• Local and intralesional therapy of in‐transit melanoma metastases

  2011cites this paper
• Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach

  2010cites this paper
• Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases

  2010cites this paper
• Étude des effets d'impulsions électriques ultra-courtes sur des cellules vivantes : mise au point de nouveaux outils, développement théorique et premières applications in vivo

  2010cites this paper